iMMagine-3
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 450 patients (estimated)
- Sponsors
- Kite, A Gilead Company
- Collaborators
- Arcellx, Inc.
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1978
- NCT Identifier
- NCT06413498
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.